OXA-48 Carbapenemase-Producing Enterobacterales in Spanish Hospitals: An Updated Comprehensive Review on a Rising Antimicrobial Resistance.

dc.contributor.authorRivera-Izquierdo, Mario
dc.contributor.authorLáinez-Ramos-Bossini, Antonio Jesús
dc.contributor.authorRivera-Izquierdo, Carlos
dc.contributor.authorLópez-Gómez, Jairo
dc.contributor.authorFernández-Martínez, Nicolás Francisco
dc.contributor.authorRedruello-Guerrero, Pablo
dc.contributor.authorMartín-delosReyes, Luis Miguel
dc.contributor.authorMartínez-Ruiz, Virginia
dc.contributor.authorMoreno-Roldán, Elena
dc.contributor.authorJiménez-Mejías, Eladio
dc.date.accessioned2025-01-07T17:19:58Z
dc.date.available2025-01-07T17:19:58Z
dc.date.issued2021-01-18
dc.description.abstractCarbapenemase-producing Enterobacterales (CPE) are significant contributors to the global public health threat of antimicrobial resistance. OXA-48-like enzymes and their variants are unique carbapenemases with low or null hydrolytic activity toward carbapenems but no intrinsic activity against expanded-spectrum cephalosporins. CPEs have been classified by the WHO as high-priority pathogens given their association with morbidity and mortality and the scarce number of effective antibiotic treatments. In Spain, the frequency of OXA-48 CPE outbreaks is higher than in other European countries, representing the major resistance mechanism of CPEs. Horizontal transfer of plasmids and poor effective antibiotic treatment are additional threats to the correct prevention and control of these hospital outbreaks. One of the most important risk factors is antibiotic pressure, specifically carbapenem overuse. We explored the use of these antibiotics in Spain and analyzed the frequency, characteristics and prevention of CPE outbreaks. Future antibiotic stewardship programs along with specific preventive measures in hospitalized patients must be reinforced and updated in Spain.
dc.identifier.doi10.3390/antibiotics10010089
dc.identifier.issn2079-6382
dc.identifier.pmcPMC7832331
dc.identifier.pmid33477731
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7832331/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2079-6382/10/1/89/pdf?version=1611034408
dc.identifier.urihttps://hdl.handle.net/10668/28326
dc.issue.number1
dc.journal.titleAntibiotics (Basel, Switzerland)
dc.journal.titleabbreviationAntibiotics (Basel)
dc.language.isoen
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectOXA-48
dc.subjectSpain
dc.subjectantibiotic stewardship
dc.subjectcarbapenem
dc.subjectcarbapenemase
dc.subjectenterobacteria
dc.subjectmultiresistant
dc.subjectoutbreak
dc.titleOXA-48 Carbapenemase-Producing Enterobacterales in Spanish Hospitals: An Updated Comprehensive Review on a Rising Antimicrobial Resistance.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7832331.pdf
Size:
724.53 KB
Format:
Adobe Portable Document Format